CAR T-cell therapy for GD2-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-phase study tests a customized immune-cell treatment (CAR T cells) that targets a protein called GD2 on lung cancer cells. It may help people with certain lung cancers that did not respond to platinum chemotherapy and who have also had treatment that blocks PD-1/PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign consent after the study procedure is explained to you
- Have an expected survival of at least 12 weeks
- Have lung cancer that did not respond to platinum chemotherapy (platinum-refractory)
- Have received or be currently receiving a PD-1 or PD-L1 blocker (immunotherapy)
- Be on steroid medicine (prednisone or equivalent), at least 10 mg per day, or meet the study doctor’s exception if below 10 mg
- Have adequate kidney, liver, and other organ function as shown by recent tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
This study tests a special immune cell treatment (CAR T cells) that targets a marker called GD2 on solid tumor cells. It is for people whose cancer has not responded to standard treatments or has come back.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.